

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

Claims 1-89. (Canceled)

Claim 90. (Previously Presented) A method of screening an antibody for activity in clearing an amyloid deposit of A $\beta$ , comprising

combining the amyloid deposit, the antibody, and microglial cells bearing Fc receptors in a medium in vitro;

by a series of measurements monitoring a reduction in the amount of the amyloid deposit remaining in the medium, the reduction in the amount of the amyloid deposit indicating the antibody has clearing activity against the amyloid-deposit.

Claim 91. (Previously Presented) The method of claim 90, wherein the amount of the amyloid deposit remaining is monitored by monitoring the amount of an antigen associated with the amyloid deposits remaining in the medium.

Claim 92. (Currently Amended) The method of claim 90, wherein the combining comprises combining the amyloid deposit and the antibody before adding the ~~phagocytic~~ microglial cells bearing Fc receptors.

Claim 93. (Previously Presented) The method of claim 90, wherein the amyloid deposit is a tissue sample from the brain of an Alzheimer's disease patient or an animal having Alzheimer's pathology.

Claim 94. (Previously Presented) The method of claim 91, wherein the antigen is A $\beta$ .

Claim 95. (Canceled)

Claim 96. (Previously Presented) The method of claim 90, wherein the monitoring is performed microscopically.

Claim 97. (Previously Presented) The method of claim 90, wherein the antibody is a monoclonal antibody.

Claim 98. (Previously Presented) The method of claim 97, wherein the antibody binds to an epitope within amino acid residues 1-7 of A $\beta$ .

Claim 99. (Canceled)

Claim 100. (Previously Presented) The method of claim 97, wherein the amyloid deposit is a tissue sample from the brain of an Alzheimer's disease patient or an animal having Alzheimer's pathology.